NCT04481646

Brief Summary

COVID-19 has become a global problem. There is an urgent need to improve the diagnosis and screening of patients and healthcare workers for COVID-19 in the UK. Mask based sampling is a method of detecting SARS-COV-2 (the virus responsible for COVID-19) in the breath of suspected COVID-19 patients or healthcare workers in the mask that they would wear in hospital. The investigators have previously demonstrated the utility of this method in other respiratory infections, such as tuberculosis. This project aims to investigate the utility of mask-based sampling is a tool for the diagnosis and quantification of COVID-19 in breath and the implications in a healthcare setting using three cohorts of participants. Initially we will compare the amount of COVID-19 detected by mask sampling compared with standard nasopharyngeal swab, which is the current gold standard test, in patients who present to hospital with COVID-19 symptoms. We will address the length of time COVID-19 is breathed out by people affected by the virus and the how infectious the virus is over time in a cohort of symptomatic healthcare workers who are isolating at home. This will allow us to understand how long someone stays infectious for and may have the potential to inform public health measures, for instance when healthcare workers can return to work or duration of isolation. Finally we will investigate asymptomatic carriage of COVID-19 by different healthcare workers in different areas of the hospital during a screening study. This will allow us to understand the extent of infection amongst healthcare workers and allow us to address hospital acquired transmission.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
630

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2020

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 12, 2020

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

July 21, 2020

Completed
1 day until next milestone

First Posted

Study publicly available on registry

July 22, 2020

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2022

Completed
3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2025

Completed
Last Updated

July 22, 2020

Status Verified

July 1, 2020

Enrollment Period

2 years

First QC Date

July 21, 2020

Last Update Submit

July 21, 2020

Conditions

Outcome Measures

Primary Outcomes (3)

  • Comparison with Naso-pharyngeal swab

    Newly diagnosed patients compare mask and swab samples taken at the same time

    6 months

  • Mask out over time

    SARS-COV-2 RNA quantification over time SARS-COV-2 RNA quantification over 21 days post diagnosis

    12 months

  • mask as a screening tool in asymptomatic people

    screening of asymptomatic healthcare workers

    6 months

Study Arms (3)

1

Patients admitted to hospital with COVID-19 symptoms will be approached to undertake a face mask sample and nasopharyngeal swab at two time points 12 hours apart on a single day whilst in hospital. Medical records will be accessed for basic clinical, demographic and microbiological data.

Diagnostic Test: Face mask sampling

2

Healthcare workers who have report COVID-19 symptoms will be asked to undertake a face mask sample and nasophayngeal swab on days 1,3,5,7,10,14 and 21 of the study, for part of which they will be quarantined at home.During this time they will complete a simple symptom diary. Medical records will be accessed for basic clinical, demographic and microbiological data.

Diagnostic Test: Face mask sampling

3

Healthcare workers from different areas of the hospital will be approached as part of a screening programme. They will be asked to undertake a single face mask and swab sample. Basic clinical and environmental data will be collected about each participant so they exposure risk can be stratified.

Diagnostic Test: Face mask sampling

Interventions

Face mask samplingDIAGNOSTIC_TEST

Mask sampling consists of a modified face mask (flat surgical, duckbilled or FFP1) which contains up to strips of 3D printed Polyvinyl alcohol (PVA). As outlined in our previous work (ref lancet). These PVA strips are manufactured by the University of Leicester and measure approximately 50mm x 500mm and are fixed into place by adhesive pads. Mask assembly is conducted at the University of Leicester and are sterilised prior to use. Figure 3 and 4 shows examples of the inside of the mask with 4 strips placed inside and of how it is worn by study participants. The mask sampling system has been approved for previous studies in the UK, South Africa and The Gambia and has current approval for service improvement work at University Hospitals of Leicester NHS Trust for respiratory pathogens. It is awaiting approval as a medical device with the Medicines and Healthcare products Regulatory Agency.

123

Eligibility Criteria

Age16 Years+
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

as previously described

You may qualify if:

  • Not requiring oxygen by face mask
  • Either:
  • o Patients admitted to hospital with suspected COVID-19
  • Or o Healthcare workers working within University Hospitals of Leicester, including those with and without symptoms suspicious of COVID-19.

You may not qualify if:

  • Participants requiring oxygen by face mask (i.e., Venturi, non rebreathe)
  • Participants with respiratory failure
  • Medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the study
  • Individuals who are unable to provide informed consent for themselves (i.e., individuals who lack capacity).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospitals of Leicester NHS Trust

Leicester, LE1 5WW, United Kingdom

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Face mask sample (exhaled sample)

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Central Study Contacts

Manish Pareek, MBChB PhD

CONTACT

Caroline Williams, MbChB

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
21 Days
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 21, 2020

First Posted

July 22, 2020

Study Start

June 12, 2020

Primary Completion

June 1, 2022

Study Completion

June 1, 2025

Last Updated

July 22, 2020

Record last verified: 2020-07

Locations